Menar­i­ni bags Stem­line and a rare dis­ease drug in $677M buy­out. But will a bet­ter of­fer fol­low?

4 years ago
Deals

Covid-19 roundup: Catal­ent signs an­oth­er Covid-19 man­u­fac­tur­ing deal; Eli Lil­ly's an­ti­body part­ner grabs $175M+

4 years ago
Coronavirus

Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

4 years ago
R&D
FDA+

High-pro­file R&D spe­cial­ist David Leb­wohl jumps to new job as CMO of a pi­o­neer­ing CRISPR play­er; Trou­bled AM­AG Phar­ma­ceu­ti­cals taps Scott My­ers as CEO

4 years ago
Peer Review

Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

4 years ago
R&D
Pharma

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

4 years ago
R&D
Coronavirus

As­traZeneca vaults to the front of the Covid-19 vac­cine race, team­ing up to glob­al­ize Ox­ford can­di­date

4 years ago
Deals
Coronavirus

Covid-19 roundup: GSK CEO Em­ma Walm­s­ley — some tri­al de­lays, but we’re lim­it­ing the dam­age — so far; Trump plan­ning ‘Warp Speed’ vac­cine plan

4 years ago
Coronavirus

Da­ta on Gilead­'s an­tivi­ral bring hope for first Covid-19 drug ap­proval

4 years ago
R&D
Coronavirus

Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

4 years ago
R&D
Coronavirus

In the heart of Texas, the AveX­is crew gath­ers for an­oth­er go at gene ther­a­py with $30M and a pow­er­house aca­d­e­m­ic pact to start

4 years ago
Financing
Startups

Sue Desmond-Hell­mann joins the mar­quee crowd of bio­phar­ma ex­perts at GV boot­ing up a new gen­er­a­tion of drug hunters

4 years ago
People

Covid-19 roundup: J&J part­ners with Catal­ent on 1B dose vac­cine goal; BioN­Tech, Pfiz­er be­gin mR­NA vac­cine tri­al in Ger­many

4 years ago
Coronavirus

Bank­ing on hope, swayed by hype? Hy­drox­y­chloro­quine in the time of Covid-19

4 years ago
FDA+
Coronavirus

Covid-19 roundup: Re­searchers claim tri­al suc­cess for Roche's Actem­ra as Alex­ion jumps in; Pfiz­er gam­bling $500M on an am­bi­tious cam­paign

4 years ago
Coronavirus

Gilead fires back in on­go­ing bat­tle with HHS, su­ing the gov­ern­ment for ‘se­cret­ly’ ob­tain­ing patents

4 years ago
R&D

An on­col­o­gy up­start with some deep-pock­et VC con­nec­tions has a uni­corn-sized ven­ture round to back the pipeline

4 years ago
Financing
Startups

Covid-19 roundup: Sanofi & Re­gen­eron de­liv­er dis­ap­point­ing news on IL-6; Alex Azar ru­mors are swirling at HHS

4 years ago
R&D
Coronavirus

#AACR20: Io­vance rev­els in promis­ing lung can­cer da­ta out of Mof­fitt as TIL ther­a­py trig­gers 2 com­plete re­spons­es

4 years ago
R&D

Eli Lil­ly ex­ecs have been think­ing about the longterm ef­fects of the pan­dem­ic and dam­age con­trol. Here’s what they be­lieve

4 years ago
People
R&D

Covid-19 roundup: Sanofi promis­es to bring re­com­bi­nant vac­cine ca­pac­i­ty to 1B+ while scal­ing up mR­NA man­u­fac­tur­ing

4 years ago
Coronavirus

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

4 years ago
R&D

Ven­rock joins the biotech VC fundrais­ing game, toss­ing $447M in­to a $4.3B pot of new mon­ey

4 years ago
Financing

‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on the chop­ping block

4 years ago
R&D
First page Previous page 203204205206207208209 Next page Last page
A service from the Financial Times